Ad-hoc | 27 February 2002 07:54

Stratec Biomedical Sys. english

Earnings per Share increased to 41 Cent in 2001 (8 x higher than Y2000’s 5 Cent) Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Earnings per Share (EPS, according to German Commercial Law) increased to 41 Cent in 2001 (8 times higher than previous fiscal year’s 5 Cent) According to § 15 WpHG, the Board of Management of STRATEC Biomedical Systems AG announces the following preliminary figures for the fiscal year 2001 (German Commercial Law): EPS 0,41 EUR (Prev. fiscal 0,05 EUR) + 720 % Annual net profit 1.243 TEUR (Prev. fiscal 158 TEUR) + 686 % EBT 1.980 TEUR (Prev. fiscal 406 TEUR) + 388 % EBIT 2.227 TEUR (Prev. fiscal 600 TEUR) + 271 % EBITDA 3.075 TEUR (Prev. fiscal 1.441 TEUR) + 113 % Turnover 27.616 TEUR (Prev. fiscal 11.086 TEUR) + 149 % Cash Flow* 1.643 TEUR (Prev. fiscal 443 TEUR) + 271 % * Cash Flow I (operational), capitalized assets were deducted due to their material significance. These preliminary figures are prior to audit and approval of the financial statement. Following its business model, STRATEC Biomedical Systems AG maintains ongoing negotiations with major diagnostics and life-science companies. The successful conclusion of contracts and completion of the design processes could lead to further significant growth of the company. end of ad-hoc-announcement (c)DGAP 27.02.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Based on its own patent-protected technologies STRATEC Biomedical Systems AG (SIN 728900) designs and manufactures fully automated systems for partners in clinical diagnostics and biotechnology. These partners sell the analyzers to laboratories and research institutes worldwide as system solutions together with their reagents. STRATEC Biomedical Systems AG is currently working on several major projects which will reach the phase of clinical testing and market launch in the periods to come. The annual report for the fiscal year 2001, which includes the figures in accordance with the International Accounting Standards (IAS) in addition to the figures in accordance with German Commercial Law, is expected to be dispatched via direct mail on April 15, 2002. Accordingly it will be made available at www.stratec-biomedical.de. For further information, please contact us at +49 (0)7082 – 791633 or ir@stratec-biomedical.de. ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Stuttgart und Frankfurt (SMAX); Freiverkehr in Berlin, Düsseldorf und Hamburg 270754 Feb 02